Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Twin Orphan Drug News

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

BioMarin Pharmaceuticals (Nasdaq: BMRN  ) keeps chugging along, pushing its orphan drug pipeline forward. Yesterday, the biotech announced data from two trials, giving the company confidence to move two programs to the next step.

First, phase 2 data for PEG-PAL, which treats phenylketonuria, looked good. The drug reduced blood Phe levels to 68% of pre-treatment baseline levels in patients treated for one year. And all those patients had Phe measurements below 600 umol/L, substantially below the 900 umol/L recommended by the National Institutes of Health.

BioMarin already has an approved drug to treat phenylketonuria, but Kuvan isn't nearly as good. Only 20% of patients reached their Phe target and the overall reduction was only 29%. PEG-PAL may cannibalize some of the Kuvan sales, but since it's much more effective, PEG-PAL will likely capture patients who would otherwise try to treat their phenylketonuria with a low Phe diet.

BioMarin plans to move PEG-PAL into phase 3 in the second quarter of 2013 after it meets with the Food and Drug Administration to get its input on the trial design.

The second trial was of the early, phase 1 variety, testing BMN-111 for achondroplasia, the most common form of dwarfism. The drug is designed to indirectly inhibit fibroblast growth factor receptor 3, which is overactive in patients with achondroplasia.

This was only a phase 1 trial in healthy patients to determine the proper dose to move into phase 2 development, but at least no safety issues were identified and BioMarin can work on designing the phase 2 proof-of-concept trial.

Moving these two drugs along is important for the overall growth of the company. BioMarin, Alexion Pharmaceutical (Nasdaq: ALXN  ) , ViroPharma (Nasdaq: VPHM  ) , and Shire (Nasdaq: SHPG  ) have made big bucks selling drugs for orphan diseases that affect relatively few individuals. But it's easy to saturate the market when there isn't any competition, leaving new products as the obvious driving force for higher revenue.

While BioMarin rules the orphan drug space, these three companies are setting themselves up to dominate retail. Find out what they are and why Fool analysts like them so much in the new free report, "3 Companies Ready to Rule Retail." Get your copy for free by clicking here now.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of BioMarin Pharmaceutical. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2034336, ~/Articles/ArticleHandler.aspx, 10/27/2016 7:09:43 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:00 PM
ALXN $131.37 Up +9.78 +8.04%
Alexion Pharmaceut… CAPS Rating: ***
BMRN $81.02 Down -0.73 -0.89%
BioMarin Pharmaceu… CAPS Rating: ****
SHPG $180.14 Up +1.19 +0.66%
Shire CAPS Rating: ***
VPHM.DL $0.00 Down +0.00 +0.00%
ViroPharma CAPS Rating: ***